Abstract

BackgroundPatient centricity has gained attention ranging from regulatory authorities to patient advocacy groups, calling for pharmaceutical companies to revise their traditional business approach to drug development by including the development of solutions that are meaningful in patients’ lives. Medication packaging is one area where empirical evidence is lacking about the incorporation of patient centricity. This study aimed to explore patient centricity applied to pharmaceutical companies’ packaging, and to identify the specific challenges faced and lessons learned when developing patient-centered packaging.MethodsThe study followed a multiple-case study research approach based on five cases of patient-centered packaging development in mid- and large-sized pharmaceutical companies.ResultsPatient-centered packaging is often associated with the intuitive and self-explanatory use of the medication by patients. Patient-centered packaging comes with challenges, but also offers opportunities for the creation of better solutions for patients and learning for the teams involved. To overcome these challenges, it is essential to build a business case that justifies such development, one where patient needs are present from the start and aligned with other imperative deadlines of drug development, with stakeholders onboard.ConclusionPatient-centered packaging is the exception rather than the norm in packaging development due to a conventional approach where packaging plays an ancillary role to drug protection. The cases presented here challenge this approach and can inspire other companies to carry out patient-centered packaging development. The cases are also relevant to other actors who are interested in continuously promoting the dialogue about patient centricity in healthcare.

Highlights

  • The pharmaceutical industry is a research and development (R&D) intensive industry

  • Research on patient centricity is fairly recent, with most of the scientific literature coupled to studies reporting on patient centricity in clinical trial processes (e.g., Gregg et al [21]), whereas studies are scarce that present the pharmaceutical industry in this area

  • The analysis of the five cases shows the choices made along the way by each company to motivate the development of a patient-centered packaging, and to engage relevant stakeholders in the conversation for patient centricity and to overcome challenges along the way

Read more

Summary

Introduction

The pharmaceutical industry is a research and development (R&D) intensive industry It is highly regulated for the safety and efficacy of the new drugs it launches in the market, and reliant on patents and market exclusivity for innovation [1]. Patient centricity has gained attention ranging from regulatory authorities to patient advocacy groups, calling for pharmaceutical companies to revise their traditional business approach to drug development by including the development of solutions that are meaningful in patients’ lives. Patient-centered packaging comes with challenges, and offers opportunities for the creation of better solutions for patients and learning for the teams involved To overcome these challenges, it is essential to build a business case that justifies such development, one where patient needs are present from the start and aligned with other imperative deadlines of drug development, with stakeholders onboard. The project was an opportunity to develop a packaging system “from scratch”, and build trust and recognition when reconstructing the drug for application focused on the innovation of treatment with reduced injections and convenience to patients

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.